Market Cap 503.67M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 693,100
Avg Vol 768,698
Day's Range N/A - N/A
Shares Out 104.06M
Stochastic %K 72%
Beta -1.47
Analysts Strong Sell
Price Target $19.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
MarketPro
MarketPro Aug. 24 at 10:53 PM
$ALMS Top Institutional Holders by Market Value. Arrows to the right: Increase / Decrease ..... Looks all green to me....
0 · Reply
SignalPathfinder
SignalPathfinder Aug. 23 at 5:21 AM
$ALMS Almado is a small cap company with limited financial disclosure and trading history posing investment risks
1 · Reply
Sportsfanbar510
Sportsfanbar510 Aug. 22 at 10:24 PM
$ALMS is this also slrn stock?
0 · Reply
BriamG316
BriamG316 Aug. 18 at 3:20 PM
$HRZN adding a little to this price, it's just a matter of time before we see a good recovery. $ALMS Excellent start to the week, already with a 50% profit, patience with good risk management pays off
0 · Reply
Piloto909
Piloto909 Aug. 18 at 3:00 PM
$ALMS love this stock! $5 looks like a new support level. Hope it holds…buying more
0 · Reply
24oldmillclear
24oldmillclear Aug. 17 at 5:41 PM
0 · Reply
BuyLowAwllHighAllWin
BuyLowAwllHighAllWin Aug. 16 at 5:14 PM
$ALMS Uptrend
0 · Reply
MarketPro
MarketPro Aug. 16 at 3:51 PM
$ALMS Top Holders by Market Value. Arrows to the Right: Additions / Reductions.
1 · Reply
777Dog
777Dog Aug. 15 at 9:08 PM
$ALMS @Kittyc803 Kitty, I am literally the only one posting over here...sleeper...take a look ....might be getting ready for a big move based upon SEC document yesterday showing loads of cash after a merger as well as a true winner pair of drugs for multi-billion dollar market...Phase 3 now fully enrolled and moving along for one of them...the other is the only oral that could treat neuroinflammatory diseases (multiple sclerosis, Parkinsons, Alzheimers etc)...multiple analysts...all buys...average target SP is 20 bucks.... If it pops, thank me... If it drops, forgive me... Best luck either way...
2 · Reply
777Dog
777Dog Aug. 15 at 8:01 PM
$ALMS Ladies and Gentlemen...that close was another higher high....yippee!
1 · Reply
Latest News on ALMS
Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 3 months ago

Alumis Completes Merger with ACELYRIN


Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 3 months ago

Alumis Stockholders Approve Merger with ACELYRIN


Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 4 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement


Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM


Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 5 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference


Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 7 months ago

Alumis Strengthens Leadership Team with Key Appointments


Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 11 months ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?


Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut


Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering


Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO


Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results


MarketPro
MarketPro Aug. 24 at 10:53 PM
$ALMS Top Institutional Holders by Market Value. Arrows to the right: Increase / Decrease ..... Looks all green to me....
0 · Reply
SignalPathfinder
SignalPathfinder Aug. 23 at 5:21 AM
$ALMS Almado is a small cap company with limited financial disclosure and trading history posing investment risks
1 · Reply
Sportsfanbar510
Sportsfanbar510 Aug. 22 at 10:24 PM
$ALMS is this also slrn stock?
0 · Reply
BriamG316
BriamG316 Aug. 18 at 3:20 PM
$HRZN adding a little to this price, it's just a matter of time before we see a good recovery. $ALMS Excellent start to the week, already with a 50% profit, patience with good risk management pays off
0 · Reply
Piloto909
Piloto909 Aug. 18 at 3:00 PM
$ALMS love this stock! $5 looks like a new support level. Hope it holds…buying more
0 · Reply
24oldmillclear
24oldmillclear Aug. 17 at 5:41 PM
0 · Reply
BuyLowAwllHighAllWin
BuyLowAwllHighAllWin Aug. 16 at 5:14 PM
$ALMS Uptrend
0 · Reply
MarketPro
MarketPro Aug. 16 at 3:51 PM
$ALMS Top Holders by Market Value. Arrows to the Right: Additions / Reductions.
1 · Reply
777Dog
777Dog Aug. 15 at 9:08 PM
$ALMS @Kittyc803 Kitty, I am literally the only one posting over here...sleeper...take a look ....might be getting ready for a big move based upon SEC document yesterday showing loads of cash after a merger as well as a true winner pair of drugs for multi-billion dollar market...Phase 3 now fully enrolled and moving along for one of them...the other is the only oral that could treat neuroinflammatory diseases (multiple sclerosis, Parkinsons, Alzheimers etc)...multiple analysts...all buys...average target SP is 20 bucks.... If it pops, thank me... If it drops, forgive me... Best luck either way...
2 · Reply
777Dog
777Dog Aug. 15 at 8:01 PM
$ALMS Ladies and Gentlemen...that close was another higher high....yippee!
1 · Reply
777Dog
777Dog Aug. 15 at 7:55 PM
$ALMS O-M-G...Yes!!!!
0 · Reply
777Dog
777Dog Aug. 15 at 7:41 PM
$ALMS were the HFT and tutes waiting to see the cash reported in an SEC document before jumping in...if so, that cash was/is the catalyst...boom!
0 · Reply
DCRMIA
DCRMIA Aug. 15 at 6:37 PM
0 · Reply
777Dog
777Dog Aug. 15 at 6:25 PM
$ALMS Is it gonna continue the slow rise...or breakout....who knows...
0 · Reply
777Dog
777Dog Aug. 15 at 6:19 PM
$ALMS Amazing... Today, Morgan Stanley analyst Terence Flynn has maintained an "Overweight" rating for Alumis (ALMS, Financial) with the price target from $23.00 to $22.00. On August 14, 2025, HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a "Buy" rating with a maintained price target of $14.00. On July 25, 2025, HC Wainwright & Co. maintained a "Buy" rating with a consistent price target of $14.00. On July 25, 2025, Wells Fargo initiated coverage on Alumis with an "Overweight" rating, announcing a price target of $17.00. On June 10, 2025, Guggenheim, through analyst Yatin Suneja, reinstated coverage with a "Buy" rating and announced a price target of $18.00. On May 15, 2025, Oppenheimer maintained an "Outperform" rating while lowering the price target from $26.00 to $25.00.
1 · Reply
777Dog
777Dog Aug. 15 at 1:03 PM
$ALMS I asked Gemini if $ALMS uses AI...put the answer with today's Cell article...$$$ "Alumis leverages a precision data analytics platform that is powered by AI and machine learning to guide its drug discovery and development efforts. This platform is a key part of the company's "precision approach" to immunology, and it's used to identify and select the right therapeutic targets, molecules, and patient populations for their treatments."
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 1:00 PM
Morgan Stanley updates rating for Alumis ( $ALMS ) to Overweight, target set at 23 → 22.
1 · Reply
777Dog
777Dog Aug. 15 at 12:54 PM
$ALMS Just my opinion, but papers like the one attached here explain why AI Pharma firms (hint: $ALMS) are gonna get gobbled up...and they are likely to be very successful...instead of screening thousands and thousands of molecules, just let Mr. Digital Wizard (AI) combined predictions from genetics and chemistry, then have a a synthesis machine make the AI-designed molecule(s) for clinical study...cures with $$$$ reward... https://www.cell.com/cell/abstract/S0092-8674(25)00855-4
0 · Reply
777Dog
777Dog Aug. 15 at 12:32 PM
$ALMS With no debt and all that cash the Enterprise Value is now only 5.09M...are we gonna get bought by whomever drove this into the ground? Downside risks are negligible since both drugs look non-toxic. Upside remains enormous (we likely have best in class and first in class in a growing multi-billion dollar market) pending expected clinical results. Full steam ahead...
0 · Reply
777Dog
777Dog Aug. 15 at 12:19 PM
$ALMS Finviz finally updated the numbers post-merger... Shs Outstand 96.86M Debt/Eq 0.08 LT Debt/Eq 0.07 Cash/s 4.72
0 · Reply
777Dog
777Dog Aug. 15 at 12:34 AM
$ALMS This is interesting...I think their target price is low...only $13...average is $20... Despite the price decline, Cantor Fitzgerald notes that the [merger] provided Alumis with "much needed capital" to fund three large ongoing clinical studies, including two in psoriasis with data expected in the first quarter of 2026 and a Phase 2b study in systemic lupus erythematosus (SLE) with results anticipated in the third quarter of 2026. The research firm believes Alumis is "in a much better position having consummated the transaction," citing that the company is now capitalized through its 2026 clinical readouts. Cantor Fitzgerald also highlighted that Alumis is now six months closer to receiving data from these clinical trials, suggesting potential catalysts ahead for the pharmaceutical company. https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-rating-on-alumis-stock-amid-postmerger-decline-93CH-4192174
0 · Reply
777Dog
777Dog Aug. 14 at 6:46 PM
$ALMS Uncle, I give up...
0 · Reply